
Multidisciplinary Collaboration Is Essential in Early-Stage NSCLC
In recent years, physicians in the field of early-stage non–small cell lung for patients with resectable disease, such as nivolumab (Opdivo) and durvalumab (Imfinzi), as well as effective targeted agents and combinations for those with unresectable disease …